Alkem Medtech Executes Supplementary Agreement for Occlutech Acquisition

Alkem Laboratories Ltd, through its wholly owned subsidiary Alkem Medtech Private Limited, has executed a First Supplementary Agreement to the Share Purchase Agreement dated March 6, 2026, concerning the acquisition of Occlutech Holding AG. This follows earlier intimations regarding Alkem Medtech's intent to acquire between 51% and 55% of Occlutech's equity share capital. The supplementary agreement was executed on June 26, 2026, with the selling shareholders of the Swiss-incorporated Occlutech. Further details will be available on the company's website.